N-(4-nitrophenyl)-2,3-diphenylquinoxaline-6-sulfonamide | 1448465-93-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: N-(4-nitrophenyl)-2,3-diphenylquinoxaline-6-sulfonamide
• CAS: 1448465-93-7
• 化学式: C₂₆H₁₈N₄O₄S
• 分子量: 482.519
• InChiKey: ZHHCIUINTIWRKO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  35
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  126
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2,3-二苯基喹喔啉 在 氯磺酸 、 sodium hydroxide 作用下， 以 水 为溶剂， 反应 8.0h， 生成 N-(4-nitrophenyl)-2,3-diphenylquinoxaline-6-sulfonamide
  参考文献：
  名称：

  Sulphonamido-quinoxalines: Search for anticancer agent

  摘要：

  A series of new sulphonamido-quinoxaline derivatives 3(a-p) have been prepared which are structurally similar to the High Throughput Screening (HTS) hit identified by Porter and collaborator. The newly synthesized compounds 3b, 3c, 3f, 3i, 3j, 3l, 3n and 3o were further evaluated in the National Cancer Institute for in vitro cytotoxicity assay among them compound 3l showed highest activity against Leukemia RPMI-8226 cell lines (GI(50): 1.11 mu M) as compared to other tested compounds. It is to be noted that compound 31 shows significant activity (GI(50): 1.11 mu M) compared to the High Throughput Screening (HTS) hit identified by Porter and collaborator (IC50 = 1.3 mu M). Further docking study confirms the c-Met kinase inhibitory mechanism of the synthesized compounds. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.04.028

文献信息

• Sulphonamido-quinoxalines: Search for anticancer agent
  作者：Rahul Ingle、Rajendra Marathe、Dipak Magar、Harun M. Patel、Sanjay J. Surana

  DOI：10.1016/j.ejmech.2013.04.028

  日期：2013.7

  A series of new sulphonamido-quinoxaline derivatives 3(a-p) have been prepared which are structurally similar to the High Throughput Screening (HTS) hit identified by Porter and collaborator. The newly synthesized compounds 3b, 3c, 3f, 3i, 3j, 3l, 3n and 3o were further evaluated in the National Cancer Institute for in vitro cytotoxicity assay among them compound 3l showed highest activity against Leukemia RPMI-8226 cell lines (GI(50): 1.11 mu M) as compared to other tested compounds. It is to be noted that compound 31 shows significant activity (GI(50): 1.11 mu M) compared to the High Throughput Screening (HTS) hit identified by Porter and collaborator (IC50 = 1.3 mu M). Further docking study confirms the c-Met kinase inhibitory mechanism of the synthesized compounds. (C) 2013 Elsevier Masson SAS. All rights reserved.